Beta Bionics announced today that a trial of its iLet bionic pancreas met key endpoints, including reduced HbA1c.
Dr. Roy W. Beck and clinical investigators presented the results of the multi-center, randomized Insulin-Only Bionic Pancreas Pivotal Trial (IO BPPT) at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans.
According to a news release, the trial met key endpoints, including consistently showing reduced mean HbA1c across populations regardless of race, education, or income level in exploratory analyses of subpopulations. Beta Bionics said that Dr. Gregory Forlenza described the study design as enabling the iLet bionic pancreas to “remove numeracy” from the management of type 1 diabetes.
Get the full story at our sister site, Drug Delivery Business News.